Shares of Janux Therapeutics (JANX) were rallying Tuesday after the biopharmaceutical company reported late Monday positive interim clinical data for its JANX007 clinical program in prostate cancer patients.

The company said high prostate-specific antigen response rates and deep PSA declines were observed in all doses in the phase 1a clinical trial, which also showed that JANX007 has a well-tolerated safety profile.

Janux said that based on these results, two once-weekly step dose regimens have been identified for phase 1b expansion trials.

Price: 61.56, Change: +21.38, Percent Change: +53.21